2023
Inflamed but not impulsive: Acute inflammatory cytokine response does not impact prepotent response inhibition
Madison A, Andridge R, Renna M, Sheridan J, Lustberg M, Ramaswamy B, Wesolowski R, Williams N, Sardesai S, Noonan A, Reinbolt R, Cherian M, Malarkey W, Kiecolt-Glaser J. Inflamed but not impulsive: Acute inflammatory cytokine response does not impact prepotent response inhibition. Journal Of Affective Disorders 2023, 342: 1-9. PMID: 37683942, PMCID: PMC10591975, DOI: 10.1016/j.jad.2023.09.008.Peer-Reviewed Original ResearchConceptsInflammatory cytokine responseCytokine responsesCancer survivorsTyphoid vaccineConners' Continuous Performance TestPostmenopausal breast cancer survivorsInterleukin-1 receptor antagonistResponse inhibitionBreast cancer survivorsInterleukin-6 responseSaline placebo injectionsOutcomes of interestPolysaccharide vaccinationPlacebo injectionsCrossover trialReceptor antagonistSeparate visitsContinuous Performance TestSecondary analysisAspects of impulsivityPlaceboNon-significant resultsPrepotent response inhibitionVaccineInjection
2021
Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias
Schnell PM, Lustberg MB, Henry NL. Adverse Events and Perception of Benefit From Duloxetine for Treating Aromatase Inhibitor-Associated Arthralgias. JNCI Cancer Spectrum 2021, 5: pkab018. PMID: 33842832, PMCID: PMC8023424, DOI: 10.1093/jncics/pkab018.Peer-Reviewed Original ResearchConceptsPatient-perceived benefitsAdverse eventsBrief Pain Inventory-Short FormAromatase Inhibitor–Associated ArthralgiaDuloxetine-treated patientsOriginal primary outcomeDouble-blind trialLow-grade toxicityEffect of duloxetineSubgroup of patientsAverage painComparable patientsAppropriate patientsPrimary outcomeMusculoskeletal symptomsBreast cancerPlaceboDuloxetineSide effectsFunctional assessmentPatientsSecondary analysisFavorable effectTreatmentPerceptions of benefits